Loading clinical trials...
Loading clinical trials...
Absorb GT1 Bioresorbable Vascular Scaffold (BVS) System Post-marketing Surveillance (PMS)
The purpose of the Surveillance is to know the frequency and status of adverse device effects and adverse events in order to assure the safety of the new medical device, and to collect efficacy and safety information for evaluating clinical use results.
Age
All ages
Sex
ALL
Healthy Volunteers
No
Nagoya Daini Red Cross Hospital
Nagoya, Aichi-ken, Japan
Shin Tokyo Hospital
Matsudo, Chiba, Japan
Shin Koga Hospital
Kurume, Fukuoka, Japan
Hanaoka Seishu Memorial Cardiovascular Clinic
Sapporo, Hokkaido, Japan
Kobe University
Kobe, Hyōgo, Japan
Iwate Medical University
Morioka, Iwate, Japan
Shonan Kamakura General Hospital
Kamakura, Kanagawa, Japan
Kurashiki Central Hospital
Kurashiki, Okayama-ken, Japan
Saitama Sekishinkai Hospital
Sayama, Saitama, Japan
Mitsui Memorial Museum
Chiyoda City, Tokyo, Japan
Start Date
December 13, 2016
Primary Completion Date
February 6, 2023
Completion Date
February 6, 2023
Last Updated
August 6, 2024
135
ACTUAL participants
ABSORB GT1 BVS
DEVICE
Lead Sponsor
Abbott Medical Devices
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06788275